Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of COX2 Inhibition on Biomarkers in Obese Breast Cancer Survivors
NCT02062255Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Oct 2013
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin and omega-3 fatty acid in breast cancer (3 arms), sponsored by UT Health San Antonio. Primary endpoint: Biomarker levels at 29 days. Started Oct 2013; status: completed.
02
Drugs
aspirinomega-3 fatty acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02062255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062255.